NCT03936452View on ClinicalTrials.gov

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 28, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeEarly StageAnlotinibPeg-aspargaseSintilimabPhase TwoOpenRadiotherapy
Interventions
DRUG

Sintilimab

Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy

Trial Locations (1)

510060

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03936452 - Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma | Biotech Hunter | Biotech Hunter